AVR 123
Alternative Names: AVR-123Latest Information Update: 30 Mar 2021
At a glance
- Originator AyuVis Research
- Class Antifibrotics; Eye disorder therapies; Small molecules
- Mechanism of Action Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Retinopathy of prematurity
Most Recent Events
- 25 Feb 2021 Preclinical trials in Fibrosis in USA (unspecified route) (AyuVis pipeline, February 2021)
- 25 Feb 2021 Preclinical trials in Retinopathy of prematurity (Prevention) in USA (unspecified route) (AyuVis pipeline, February 2021)
- 25 Feb 2021 Preclinical trials in Retinopathy of prematurity in USA (unspecified route) (AyuVis pipeline, February 2021)